PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 11.74M 10.2M 9.52M 8.74M 16.49M 1.12B 16.77M 112M 43.98M 558M 44.09M 43.11M 1.84B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 16.65M 14.47M 13.51M 12.4M 23.38M 1.59B 23.79M 159M 62.38M 791M 62.53M 61.15M 2.61B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/08/24	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/06/24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/06/24	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/01/24	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/12/23	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/05/23	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/05/23	PCL to Raise 36 Billion Won via Share Issuance	MT
23/03/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/12/22	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	352,666.67
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.11%	11.69M
VERACYTE, INC.	-1.75%	-17.85%	+87.85%	+79.30%	3.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+4.01%	+3.99%	+114.85%	+236.30%	3.59B
CAREDX, INC.	+9.24%	+32.74%	+283.06%	+349.82%	2.26B
BGI GENOMICS CO., LTD.	-0.42%	+4.11%	-27.65%	-35.55%	2.17B
IOVANCE BIOTHERAPEUTICS, INC.	+5.77%	-11.73%	+52.83%	-40.18%	1.82B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.21%	-3.66%	+183.92%	-46.56%	969M
SEEGENE, INC.	-0.74%	-2.55%	-8.09%	+20.27%	853M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.46%	+7.96%	-37.98%	-10.07%	511M
CURIOX BIOSYSTEMS CO., LTD	+2.80%	-0.52%	+2.52%	-	449M
Average	+1.62%	-1.44%	+65.13%	+51.69%	1.64B
Weighted average by Cap.	+2.25%	-3.01%	+95.91%	+110.06%

	2023	2024
Net sales	8.43B 5.89M 5.12M 4.78M 4.39M 8.27M 561M 8.41M 56.33M 22.06M 280M 22.12M 21.63M 923M	1.25B 870K 757K 706K 648K 1.22M 82.97M 1.24M 8.33M 3.26M 41.38M 3.27M 3.2M 136M
Net income	-20.32B -14.19M -12.33M -11.52M -10.57M -19.93M -1.35B -20.28M -136M -53.18M -675M -53.31M -52.13M -2.23B	-52.34B -36.56M -31.77M -29.66M -27.23M -51.35M -3.48B -52.24M -350M -137M -1.74B -137M -134M -5.73B
Net Debt	7.2B 5.03M 4.37M 4.08M 3.75M 7.07M 480M 7.19M 48.15M 18.86M 239M 18.9M 18.48M 789M	7.03B 4.91M 4.27M 3.98M 3.66M 6.9M 468M 7.02M 46.98M 18.4M 233M 18.45M 18.04M 770M